Catalyst

Slingshot members are tracking this event:

Kite Expects Initial Phase 1 ZUMA-3 Data Evaluating KTE-C19 in Adult Acute Lymphoblastic Lymphoma in 2016

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
KITE

100%

Additional Information

Clinical Data Update on Jun 5, 2017: Full Data Released
http://ir.kitepharma...
Slingshot Insights Explained
Catalyst Date
Occurred on:
Dec 04, 2016
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 1, Zuma-3, Kte-c19, Aggressive Non-hodgkin Lymphoma